Edition:
India

Arbutus Biopharma Corp (ABUS.OQ)

ABUS.OQ on NASDAQ Stock Exchange Global Select Market

1.50USD
16 Aug 2019
Change (% chg)

$0.08 (+5.63%)
Prev Close
$1.42
Open
$1.45
Day's High
$1.53
Day's Low
$1.45
Volume
35,445
Avg. Vol
131,979
52-wk High
$11.20
52-wk Low
$1.39

Latest Key Developments (Source: Significant Developments)

Arbutus Biopharma Q2 Loss Per Share $0.46
Monday, 5 Aug 2019 

Arbutus Biopharma Corp ::ARBUTUS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.46.Q2 EARNINGS PER SHARE ESTIMATE $-0.37 -- REFINITIV IBES DATA.SAYS RECEIVED $20 MILLION IN GROSS PROCEEDS FROM SALE OF A PORTION OF ONPATTRO ROYALTY ENTITLEMENT.CO BELIEVES ITS CASH AND INVESTMENTS BALANCE IS SUFFICIENT TO FUND OPERATIONS INTO SECOND HALF OF 2020.ANTICIPATE MOVING INTO A COMBINATION PROOF-OF-CONCEPT PHASE 2 CLINICAL TRIAL IN SUBJECTS WITH CHRONIC HEPATITIS B IN H2 2020.  Full Article

Veritas Reaches A Mutual Settlement With Arbutus Biopharma Corporation
Wednesday, 24 Jul 2019 

July 23 (Reuters) - Veritas Pharma Inc ::VERITAS REACHES A MUTUAL SETTLEMENT WITH ARBUTUS BIOPHARMA CORPORATION.VERITAS PHARMA INC - HAS ENTERED INTO A CONFIDENTIAL SETTLEMENT THAT WILL RESOLVE THE ARBUTUS BIOPHARMA LITIGATION COMPLETELY.VERITAS PHARMA - REACHED SETTLEMENT WITH ARBUTUS BIOPHARMA REGARDING LITIGATION COMMENCED BY ARBUTUS FOR CLAIMS RELATED TO A COMMERCIAL LEASE SPACE.  Full Article

Arbutus Announces Preliminary Early-Stage Clinical Trial Results For AB-506
Tuesday, 16 Jul 2019 

July 15 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS ANNOUNCES PRELIMINARY PHASE 1A/1B CLINICAL TRIAL RESULTS FOR AB-506, AN ORAL CAPSID INHIBITOR IN DEVELOPMENT FOR PEOPLE WITH CHRONIC HEPATITIS B.ARBUTUS BIOPHARMA CORP - PHASE 1A/1B CLINICAL TRIAL TO CONTINUE WITH ENROLLMENT OF FURTHER COHORTS.ARBUTUS BIOPHARMA CORP - NO SERIOUS ADVERSE EVENTS OR CLINICALLY SIGNIFICANT SAFETY FINDINGS WERE OBSERVED IN HEALTHY SUBJECTS FOR AB-506.ARBUTUS BIOPHARMA CORP - NO SERIOUS ADVERSE EVENTS WERE OBSERVED IN CHRONIC HEPATITIS B SUBJECTS.  Full Article

Arbutus Sells Part Of Its Onpattro Royalty Interest To Omers
Wednesday, 3 Jul 2019 

July 2 (Reuters) - Arbutus Biopharma Corp ::PRESS RELEASE - ARBUTUS SELLS PART OF ITS ONPATTRO™ (PATISIRAN) ROYALTY INTEREST TO OMERS.ARBUTUS BIOPHARMA CORP - ARBUTUS TO RECEIVE $20 MILLION IN GROSS PROCEEDS BEFORE ADVISORY FEES WHILE RETAINING SIGNIFICANT DOWNSTREAM ECONOMICS.ARBUTUS BIOPHARMA CORP - RUNWAY EXTENDED WITH NON-DILUTIVE CAPITAL.ARBUTUS BIOPHARMA CORP - ARBUTUS IS ENTITLED TO TIERED ROYALTY PAYMENTS ON NET SALES OF ONPATTRO RANGING FROM 1.00% - 2.33% AFTER OFFSETS.ARBUTUS BIOPHARMA CORP - ROYALTY INTEREST HAS BEEN SOLD TO OMERS, EFFECTIVE AS OF JANUARY 1, 2019, FOR $20 MILLION.  Full Article

Arbutus Q1 Loss Per Share $0.47
Tuesday, 7 May 2019 

May 6 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.47.Q1 EARNINGS PER SHARE ESTIMATE $-0.32 -- REFINITIV IBES DATA.HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALING $110.6 MILLION AS OF MARCH 31, 2019.BELIEVE CASH AND INVESTMENTS BALANCE IS SUFFICIENT TO FUND OPERATIONS INTO 2020.  Full Article

Arbutus Reports Q3 Loss Per Share $0.49
Thursday, 8 Nov 2018 

Nov 7 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS REPORTS 2018 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.49.Q3 REVENUE $1.6 MILLION VERSUS $6.9 MILLION.Q3 REVENUE VIEW $211,000 -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.41 -- THOMSON REUTERS I/B/E/S.  Full Article

Arbutus Appoints David Hastings As Chief Financial Officer
Friday, 8 Jun 2018 

June 7 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS STRENGTHENS MANAGEMENT TEAM WITH APPOINTMENT OF DAVID C. HASTINGS AS NEW CHIEF FINANCIAL OFFICER.ARBUTUS BIOPHARMA CORP - HASTINGS WILL ASSUME CFO ROLE FROM KOERT VANDENENDEN, ARBUTUS' INTERIM CHIEF FINANCIAL OFFICER..ARBUTUS BIOPHARMA CORP - APPOINTMENT OF DAVID HASTINGS AS CHIEF FINANCIAL OFFICER, EFFECTIVE JUNE 11.  Full Article

Arbutus Announces Corporate Update
Thursday, 15 Mar 2018 

March 14 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS ANNOUNCES CORPORATE UPDATE AND YEAR-END 2017 FINANCIAL RESULTS.ARBUTUS BIOPHARMA CORP - ‍ARB-1467 PHASE II COMBINATION STUDY BEGINNING IN 1Q18​.ARBUTUS BIOPHARMA CORP - ‍INTERIM ON-TREATMENT RESULTS FROM ARB-1467 STUDY ARE EXPECTED IN SECOND HALF OF 2018, FOLLOWED BY FINAL RESULTS IN 2019 ​.ARBUTUS BIOPHARMA CORP - ‍AB-452 TO ENTER CLINICAL DEVELOPMENT​.  Full Article

Arbutus Settles Litigation Terminating Acuitas Rights To LNP Technology
Friday, 23 Feb 2018 

Feb 22 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS SETTLES LITIGATION, TERMINATING ACUITAS’ RIGHTS TO LNP TECHNOLOGY.ARBUTUS BIOPHARMA CORP - ‍SETTLEMENT TERMINATES ACUITAS' RIGHT TO USE OR SUBLICENSE OUR LNP TECHNOLOGY GOING FORWARD​.ARBUTUS BIOPHARMA - ‍SETTLEMENT STIPULATES THAT 4 NON-EXCLUSIVE VIRAL VACCINE SUBLICENSES PREVIOUSLY GRANTED TO MODERNA ARE ONLY SUBLICENSES TO SURVIVE​.ARBUTUS BIOPHARMA - LITIGATION INITIATED BY ACUITAS THERAPEUTICS ON OCT. 25, 2016 IN SUPREME COURT OF BRITISH COLUMBIA HAS BEEN SETTLED BEFORE TRIAL​.  Full Article

Arbutus Announces Departure Of CFO Bruce Cousins
Wednesday, 14 Feb 2018 

Feb 13 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER; APPOINTS INTERIM CFO.BRUCE COUSINS, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, IS LEAVING CO BUT WILL REMAIN AVAILABLE ON A CONSULTING BASIS.‍KOERT VANDENENDEN, ARBUTUS' VICE PRESIDENT OF FINANCE, WILL SERVE AS INTERIM CHIEF FINANCIAL OFFICER​.‍COMPANY WILL PROMPTLY BEGIN A SEARCH FOR A PERMANENT CHIEF FINANCIAL OFFICER.​.  Full Article